
Hematopoietic Stem Cell Transplantation - Pipeline Insight, 2024
Description
Hematopoietic Stem Cell Transplantation - Pipeline Insight, 2024
DelveInsight’s, “Hematopoietic Stem Cell Transplantation - Pipeline Insight, 2024,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Hematopoietic Stem Cell Transplantation pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Hematopoietic Stem Cell Transplantation: Overview
Bone marrow transplant (hematopoietic stem cell transplant) (HPSCT) involves the administration of healthy hematopoietic stem cells in patients with dysfunctional or depleted bone marrow. This helps to augment bone marrow function and allows, depending on the disease being treated, to either destroy tumor cells with malignancy or to generate functional cells that can replace the dysfunctional ones in cases like immune deficiency syndromes, hemoglobinopathies, and other diseases. The main component of bone marrow which ensures hematopoetic regeneration is the pluripotent stem cell - which has been characterised by immunophenotyping (identification of the cell surface protein/ antigen CD34+ will demarcate cells represent a heterogeneous group including the most primitive blood forming stem cell). Depending upon the donor, the transplantation is called allogeneic, autologous or syngeneic. In each case, the source of these hematopoietic stem cells could be the bone marrow, peripheral blood or umbilical cord blood as mentioned above. In allogeneic bone marrow transplant (allo BMT) the normal hematopoietic stem cells are derived from a HLA matched donor. The donor may or may not be related to the patient (matched sibling donor BMT or matched unrelated donor BMT). In syngenic BMT the donor is an HLA identical twin sibling. In autologous BMT (ABMT) the patient's own stem cells are harvested during remission and used for 50 Years of Cancer Control in India 139 139 hematopoiec rescue after supralethal chemoradiotherapy. The mechanism by which allo BMT is supposed to cure malignancy is by the anti cancer effect of drugs as well as by the immunological reaction between graft and cancer cells known as graft versus leukemia effect (GVL).
""Hematopoietic Stem Cell Transplantation- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hematopoietic Stem Cell Transplantation pipeline landscape is provided which includes the disease overview and Hematopoietic Stem Cell Transplantation treatment guidelines. The assessment part of the report embraces, in depth Hematopoietic Stem Cell Transplantation commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence in Hematopoietic Stem Cell Transplantation R&D. The therapies under development are focused on novel approaches to treat/improve in Hematopoietic Stem Cell Transplantation.
- Iomab-B is currently being studied in the pivotal Phase 3 SIERRA (Study of Iomab-B in Elderly Relapsed or Refractory AML) trial, a 150-patient, randomized controlled clinical trial in patients with relapsed or refractory acute myeloid leukemia (AML) who are age 55 and above. Patient enrollment in the SIERRA trial was completed in the third quarter of 2021 and the last patient on SIERRA was transplanted in the fourth quarter of 2021. Topline data results are expected in the third quarter of 2022.
Hematopoietic Stem Cell Transplantation Emerging Drugs
- Iomab-B: Actinium Pharmaceuticals
- Motixafortide: BioLineRx
MANA-312: Mana therapeutics
MANA-312 is an allogeneic donor-derived cell therapy for the treatment of acute myeloid leukemia (AML) in the relapsed refractory post-transplant setting. It is the same product tested in the initial RESOLVE study performed at Children’s National Hospital and Johns Hopkins Medical Center, though enhanced by improvements to the manufacturing process approved by the FDA. The source of the cells is the same donor who provides bone marrow or a leukapheresis for the original bone marrow transplant.
Further product details are provided in the report……..
Hematopoietic Stem Cell Transplantation: Therapeutic Assessment
This segment of the report provides insights about the different Hematopoietic Stem Cell Transplantation drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Hematopoietic Stem Cell Transplantation
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intravenous
- Molecule Type
- Peptide
- Protein
- Propylene glycols
- Cell Therapy
- Product Type
Hematopoietic Stem Cell Transplantation: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hematopoietic Stem Cell Transplantation therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hematopoietic Stem Cell Transplantation drugs.
Hematopoietic Stem Cell Transplantation Report Insights
- Hematopoietic Stem Cell Transplantation Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Hematopoietic Stem Cell Transplantation drugs?
- How many Hematopoietic Stem Cell Transplantation drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hematopoietic Stem Cell Transplantation?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hematopoietic Stem Cell Transplantation therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Hematopoietic Stem Cell Transplantation and their status?
- What are the key designations that have been granted to the emerging drugs?
- Actinium Pharmaceuticals
- BioLineRx
- Athersys
- Novartis
- CareDex
- Orchard Therapeutics
- Magenta Therapeutics
- Graphite Bio
- Vor Biopharma
- Jasper Therapeutics
- Garuda Therapeutics
- Iomab-B
- Motixafortide
- HSC Transplant / GvHD
- AlloHeme
- OTL-200
- MGTA 145
- GPH101
- VOR33
- JSP191
Table of Contents
80 Pages
- Introduction
- Executive Summary
- Hematopoietic Stem Cell Transplantation: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Hematopoietic Stem Cell Transplantation – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Iomab-B: Actinium Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- MGTA 145: Magenta Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- VOR33: VOR Bio Pharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- MANA-312: Mana therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Hematopoietic Stem Cell Transplantation Key Companies
- Hematopoietic Stem Cell Transplantation Key Products
- Hematopoietic Stem Cell Transplantation- Unmet Needs
- Hematopoietic Stem Cell Transplantation- Market Drivers and Barriers
- Hematopoietic Stem Cell Transplantation- Future Perspectives and Conclusion
- Hematopoietic Stem Cell Transplantation Analyst Views
- Hematopoietic Stem Cell Transplantation Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.